Trial Profile
A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms A.R.R.O.W.; ARROW
- Sponsors Amgen; Ono Pharmaceutical; Onyx Pharmaceuticals
- 01 Oct 2022 Results of post-hoc pooled analysis assessing cardiovascular risk factors and cardiovascular disease data from four clinical studies: ASPIRE, ARROW, FOCUS, ENDEAVOR published in the Clinical Lymphoma, Myeloma & Leukemia
- 22 Nov 2019 According to an Ono Pharmaceutical media release, the company has received an approval for KYPROLIS for Intravenous Injection 10 mg and 40 mg ("Kyprolis"), in Japan for additional dosage and administration in patients with relapsed or refractory multiple myeloma, for a partial change in approved items of the manufacturing and marketing approval.
- 12 Sep 2019 According to an Amgen media release, data from this trial will be presented at the 17th International Myeloma Workshop (IMW) 2019 in Boston, Sept. 12-15, 2019.